Highlights

  • Chrysos Corporation (ASX:C79) reported FY26 revenue of AUD 88.1mn, up 33% YoY.
  • FY26 EBITDA increased 68% YoY to AUD 27.2mn, with a reported 31% margin.
  • PhotonAssay processed 11.3mn samples during FY26, a 67% YoY increase.
  • The company reported 87 contracted units and FY27 revenue guidance of AUD 108mn–118mn.

Chrysos Corporation develops and leases PhotonAssay systems that analyse gold and other elements for miners and commercial laboratories. Following an expansion in instrument deployments and sample processing during FY26, Chrysos Corporation (ASX:C79) shares closed at AUD 6.67 on 27 October 2026, up approximately 0.91% for the session. Its annual results set out how an enlarged contracted fleet, greater use of installed instruments and manufacturing capacity feature in the company’s FY27 operating plans.

Company Business

Chrysos Corporation (ASX:C79) commercialises PhotonAssay, an analytical technique using high-energy X-rays to measure gold and other elements in mineral samples. Its equipment is installed at laboratory and mining sites, allowing users to process samples without relying exclusively on conventional fire-assay methods. The company supplies and supports its instruments under leases rather than primarily through outright equipment sales.

Revenue includes minimum monthly assay payments under contracts and additional assay charges linked to volumes above contracted thresholds. Consequently, the number of deployed instruments and their utilisation both affect operating performance. Chrysos has customers and sites in Australia, Canada, Africa and South America. Its customer network includes laboratory groups and directly contracted mine operators, bringing exposure to production testing as well as mineral exploration work.

Recent Development

In August 2026, Chrysos Corporation (ASX:C79) released results for the year ended 30 June 2026. The company reported 24 new lease agreements signed during FY26, followed by four further agreements after the reporting period. This brought the contracted fleet to 87 units, compared with 59 at the preceding year-end. Seven instruments were deployed during FY26, with six further units in the deployment process at the time of the annual announcement.

The operational programme included a first PhotonAssay deployment in Chile and the introduction of the next-generation XN instrument in Perth. Agreements announced after the reporting period extended the company’s prospective deployment footprint into Peru and Mexico. Management also reported that manufacturing capability had reached a targeted rate of 18 units annually; actual site commissioning depends on customer readiness, infrastructure and regulatory requirements.

A key distinction in the company’s operating disclosures is between contracted systems, equipment being deployed and instruments already producing billable assays. Chrysos Corporation (ASX:C79) must convert agreements into operating installations before all associated recurring charges can commence. Actual assay throughput then determines the scope for additional volume-based revenue.

Financial Performance and Sector Context

Chrysos Corporation (ASX:C79) recorded FY26 revenue of AUD 88.1mn, compared with AUD 66.1mn in FY25, an increase of 33%. EBITDA increased to AUD 27.2mn from AUD 16.1mn, up 68%. The EBITDA margin consequently moved from approximately 24% to 31%. These changes reflected both a larger deployed base and increased activity across operating units.

Annual sample volumes reached 11.3mn, up 67% YoY, and volumes exceeded one million samples per month for five consecutive months from March 2026. The company reported FY26 net operating cash inflows of AUD 17.9mn. At year-end, it had AUD 25.9mn in cash and AUD 140mn of undrawn debt facilities available, resources relevant to planned manufacturing and equipment installation spending.

The FY26 results announcement set FY27 revenue guidance at AUD 108mn–118mn and EBITDA guidance at AUD 35mn–42mn, based on stated constant-currency assumptions. These are company targets rather than realised results. Mine production schedules, gold-testing demand, exploration activity and laboratory customers’ adoption of alternative analysis processes influence utilisation. Changes in currency rates can also affect reported group results given its international activities.

Risks to Consider

Chrysos Corporation (ASX:C79) faces execution risk when manufacturing, transporting and commissioning sophisticated instruments across different jurisdictions. Installation delays can shift the timing of contracted revenue. Equipment reliability, service requirements and customer concentration can influence costs and assay volumes. The business also depends on mining-sector activity and faces foreign-exchange exposure, while its capital commitments and debt facilities require ongoing cash-flow management.

What to Watch Next

The next disclosures from Chrysos Corporation (ASX:C79) will indicate whether instrument installations move from the contracted pipeline into revenue-producing operation on schedule. Relevant measures include deployed-unit numbers, monthly sample volumes, additional assay charges and reported cash generation. Investors can also compare FY27 trading updates against the published revenue and EBITDA guidance, while monitoring the commercial rollout of the XN platform and further geographic deployments.

Key Insights

Chrysos Corporation (ASX:C79) increased FY26 revenue, EBITDA and assay volumes as its PhotonAssay fleet expanded. The distinction between 87 contracted units and those already deployed remains central to the implementation programme. FY27 performance will depend on conversion of contracts into operating systems, utilisation across the fleet and management of funding and deployment costs.